INSILICO MEDICINE
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digita... l medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
INSILICO MEDICINE
Industry:
Artificial Intelligence Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Hong Kong, Hong Kong Island, Hong Kong
Country:
Hong Kong
Website Url:
http://www.insilico.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
401.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics Euro COVID-19
Similar Organizations
3billion
3billion is a world leader in the field of genetic diagnostics for rare disease.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
HelixNano
Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases.
Fabric Genomics (formerly Omicia)
Global healthcare platform for genomics-driven precision medicine. Fabric' proven AI algorithms power genomic insights.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
B Capital Group
B Capital Group investment in Series D - Insilico Medicine
BHR Partners
BHR Partners investment in Series D - Insilico Medicine
Prosperity7 Ventures
Prosperity7 Ventures investment in Series D - Insilico Medicine
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati investment in Series D - Insilico Medicine
Deerfield
Deerfield investment in Series D - Insilico Medicine
Pavilion Capital
Pavilion Capital investment in Series D - Insilico Medicine
Warburg Pincus
Warburg Pincus investment in Series D - Insilico Medicine
Qiming Venture Partners
Qiming Venture Partners investment in Series D - Insilico Medicine
Bold Capital Partners
Bold Capital Partners investment in Series D - Insilico Medicine
Bold Capital Partners
Bold Capital Partners investment in Series D - Insilico Medicine
Newest Events participated
Participated in Women in AI in Healthcare Dinner, London 2017
on 2017-11-22 as sponsor
Key Employee Changes
Official Site Inspections
http://www.insilico.com Semrush global rank: 2.2 M Semrush visits lastest month: 8.88 K
- Host name: 185.215.4.66
- IP address: 185.215.4.66
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Insilico Medicine"
Insilico Medicine - Wikipedia
Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery. See details»
Mission | Insilico Medicine
The company's team is distributed globally, allowing the company to establish a local presence in key geographies, with office sites or R&D talents in the U.S., Greater China, Canada, and the Middle East to support recruitment of top …See details»
Team | Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in generative artificial intelligence technologies for drug discovery and biomarker development.Dr. Zhavoronkov has a combined …See details»
Insilico Medicine - Crunchbase Company Profile
Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life …See details»
Insilico Medicine | World Economic Forum
The World Economic Forum is an independent international organization committed to improving the state of the world by engaging business, political, academic and other leaders of society to shape global, regional and industry …See details»
Insilico - Crunchbase Company Profile & Funding
Insilico is a company that provides new material development and system construction services with a new high-efficiency/low-cost methodology based on IT and material convergence …See details»
Insilico Moves HQ to Cambridge, MA, Completes IPF …
Jun 20, 2024 Most of Insilico’s revenue, $39.022 million or 76%, came from pipeline drug development, which includes R&D and out-licensing of some drug candidates to biopharmas, while another 17% or $8.976 ...See details»
Alex Zhavoronkov – Founder & CEO, Insilico Medicine
Aug 21, 2023 How internationalised is Insilico today and how does it draw on the different geographies in which it has a footprint? We have infrastructure across the world. In the US, Insilico has business development (BD), …See details»
Insilico Medicine Opens Largest AI-Powered Biotechnology
Jan 2, 2023 Insilico Medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS), and aging-related …See details»
Insilico enters into research collaboration with Pfizer Inc. to explore ...
HONG KONG – Jan. 14, 2020 – Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico’s machine learning …See details»
20 Things You Didn’t Know About Insilico Medicine - Money Inc
Oct 13, 2021 NVIDIA named Insilico to its list of the top five artificial intelligence companies in 2017. The organization cited that Insilico has a tremendous potential to make a positive social …See details»
Insilico Medicine Raises $255 Million in Series C Financing
Jun 22, 2021 NEW YORK and HONG KONG, June 22, 2021 /CNW/ -- Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and …See details»
Insilico Medicine launches 6th generation Intelligent Robotics Lab …
Insilico Medicine’s lab takes this process one step further to incorporate AI in decision-making and deeply integrate AI with automation, robotics, and biological capabilities to enable a new ...See details»
Insilico Medicine Announces Strategic Collaboration with EQRx to ...
Mar 24, 2022 The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's …See details»
Insilico Medicine Signs Strategic Research Collaboration
New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic …See details»
PandaOmics - Insilico
Nov 8, 2017 We have had discussions with several AI startups and Insilico Medicine is the only company which provides excellent service not only with collaboration but also with software …See details»
PHARMA.AI - Insilico
Commercially-available end-to-end generative Al software and robotics platform designed to improve the quality and productivity of pharmaceutical researchSee details»
Pipeline | Insilico Medicine
The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery capabilities of our Pharma.AI platform consisting of Biology42, Chemistry42, and Medicine42.See details»
Why Insilico Medicine is one of the most innovative companies of …
Mar 19, 2024 Insilico intends to submit an investigational new drug application for the candidate in the second half of 2024. advertisement. Explore the full 2024 list of Fast Company’s ...See details»